Embedded Files
THE EFFECT OF TOPICAL STEROID AND ORAL GABAPENTIN IN THE TREATMENT OF CAPECITABINE INDUCE HAND FOOT SYNDROME AMONG CANCER PATIENTS
THE EFFECT OF TOPICAL STEROID AND ORAL GABAPENTIN IN THE TREATMENT OF CAPECITABINE INDUCE HAND FOOT SYNDROME AMONG CANCER PATIENTS
Harez Othman Hassan a and Mohammed Omer Mohammed b
a College of Pharmacy, University of Sulaimani, Kurdistan Region, Iraq.
b College of Medicine, University of Sulaimani, Kurdistan Region, Iraq.
Submitted: 14/9/2020; Accepted: 3/2/2021; Published: 21/9/2021
DOI Link: https://doi.org/10.17656/jsmc.10312
ABSTRACT
Background
Cancer patients facing many complications during treatments, such as oral Mucositis, neuropathy, and chemotherapy-induced diarrhoea. Unique toxicities can accompany Specific routes of administration of colon cancer drugs such as hand-foot syndrome.
Objectives
To study the effects of topical steroids and oral gabapentin in treating capecitabine induce hand-foot syndrome among cancer patients.
Patients and Methods
A total of 50 patients diagnosed with hand-foot syndrome attended in Hiwa cancer hospital in Sulaimani-Iraq, who met the inclusion criteria, were enrolled in the current study from august 2019-February 2020. patient’s characteristics, concomitant drugs Used, any other diseases were recorded in a questionnaire designed for the study. Grading of the hand-foot syndrome and its severity of presentation is done by Using NCI-CTCAE (National Cancer Institute - Common Terminology Criteria for Adverse Events) and WHO (World Health Organization) and associated histologic findings. In addition, the quality of Life of the Patients was evaluated by using RAND 36-item short forming survey (SF36); The DN4 scale measured the neuropathy of Patients.
Results
The grades of the hand-foot syndrome after treatment were significantly improved compared to pretreatment (p-value; ≥0.001). Moreover, it changed the frequency of hand-foot syndrome by using topical steroids (clobetasol 0.05%), gabapentin, or both.
Conclusion
The study showed a statistically significant improvement in grades of the hand-foot syndrome of participants and increasing quality of life through using topical Steroids and gabapentin.
KEYWORDS
Capecitabine, Hand-foot syndrome, Clobetasol, gabapentin, Quality of life SF36.
References
1. Lassere Y, Hoff P. Management of hand-foot syndrome in patients treated with capecitabine (Xeloda®). European Journal of Oncology Nursing. 2004;8:S31-S40.
2. Nagore E, Insa A, Sanmartín O. Antineoplastic Therapy—Induced Palmar Plantar Erythrodysesthesia (‘Hand-Foot’) Syndrome. American journal of clinical dermatology. 2000;1(4):225-3.
3. Gressett SM, Stanford BL, Hardwicke F. Management of hand-foot syndrome induced by capecitabine. Journal of Oncology Pharmacy Practice. 2006;12(3):131-41.
4.Miller KK, Gorcey L, McLellan BN. Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management. Journal of the American Academy of Dermatology. 2014;71(4):787-94.
5. Caronia D, Martin M, Sastre J, De La Torre J, García-Sáenz JA, Alonso MR, et al. A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome. Clinical Cancer Research. 2011;17(7):2006-13.
6. Nikolaou V, Syrigos K, Saif M. Incidence and implications of chemotherapy-related hand-foot syndrome. Expert opinion on drug safety. 2016;15(12):1625-33.
7. Degen A, Alter M, Schenck F, Satzger I, Völker B, Kapp A, et al. The hand-foot-syndrome associated with medical tumor therapy–classification and management. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2010;8(9):652-61.
8. Braghiroli CS, Ieiri R, Ocanha JP, Paschoalini RB, Miot HA. Do you know this syndrome? Hand-foot syndrome. Anais brasileiros de dermatologia. 2017;92(1):131-3.
9. Ishizaka K, Nomizu T, Kitao A. Preventive and therapeutic agent of hand-foot syndrome. Google Patents; 2014.
10. Saif MW. Capecitabine and hand-foot syndrome. Expert opinion on drug safety. 2011;10(2):159-69.
11. Ulrich J, Hartmann JT, Dörr W, Ugurel S. Skin toxicity of anti-cancer therapy. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2008;6(11):959-75.
12. Silva D, Gomes A, MS Lobo J, Almeida V, Almeida IF. Management of skin adverse reactions in oncology. Journal of Oncology Pharmacy Practice. 2020:1078155220936341.
13. Orwelius L, Nordlund A, Nordlund P, Simonsson E, Bäckman C, Samuelsson A, et al. Pre-existing disease: the essential factor for health-related quality life long-term after critical illness: a prospective, longitudinal, multicentre trial. Critical Care. 2010;14(2): R67.
14. Orwelius L, Nilsson M, Nilsson E, Wenemark M, Walfridsson U, Lundström M, et al. The Swedish RAND-36 Health Survey-reliability and responsiveness assessed in patient populations using Svensson’s method for paired ordinal data. Journal of patient-reported outcomes. 2018;2(1):4.
15. Garratt AM, Ruta DA, Abdalla MI, Buckingham JK, Russell IT. The SF36 health survey questionnaire: an outcome measure suitable for routine use within the NHS? British Medical Journal. 1993;306(6890):1440-4.
16. Benson AB, Venook AP, Cederquist L, Chan E, Chen Y-J, Cooper HS, et al. Colon cancer, version 1.2017, NCCN clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network. 2017;15(3):370-98.
17. Kurt M, Aksoy S, Guler N. Could the hand-foot syndrome after capecitabine treatment be associated with better outcomes in metastatic breast cancer patients? : Taylor & Francis; 2006.
18. Son H-S, Lee WY, Lee W-S, Yun SH, Chun H-K. Compliance and effective management of the hand-foot syndrome in colon cancer patients receiving capecitabine as adjuvant chemotherapy. Yonsei medical journal. 2009;50(6):796-802.
19. Sibaud V, Dalenc F, Chevreau C, Roché H, Delord J-P, Mourey L, et al. HFS-14, a specific quality of life scale developed for patients suffering from the hand-foot syndrome. The oncologist. 2011;16(10):1469.
20. Abushullaih S, Saad ED, Munsell M, Hoff PM. Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: a single-institution experience. Cancer investigation. 2002;20(1):3-10.
21. Kawakami K, Yokokawa T, Kobayashi K, Sugisaki T, Suzuki K, Suenaga M, et al. Self-reported adherence to capecitabine on XELOX treatment as adjuvant therapy for colorectal cancer. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics. 2017;25(9):1625-31.
22. Zhang R-X, Wu X-J, Lu S-X, Pan Z-Z, Wan D-S, Chen G. The effect of COX-2 inhibitor on the capecitabine-induced hand-foot syndrome in patients with stage II/III colorectal cancer: a phase II randomized prospective study. Journal of cancer research and clinical oncology. 2011;137(6):953-7.
23. Yap Y-S, Kwok L-L, Syn N, Chay WY, Chia JWK, Tham CK, et al. Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine–Induced Hand-Foot Syndrome: A Randomized Clinical Trial. JAMA oncology. 2017;3(11):1538-45.
24. Zhao Y, Ding Y, Lu Y, Zhang J, Gu J, Li M. Incidence and self-management of hand-foot syndrome in patients with colorectal cancer. Clin J Oncol Nurs. 2013;17(4):434-7.
© The Authors, published by University of Sulaimani, College of Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Page updated
Report abuse